NASDAQ$RPRX
Royalty Pharma PLC · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Royalty Pharma reported financial results and raised full-year 2022 guidance for Adjusted Cash Receipts.
Royalty Pharma reported a decrease in total income and other revenues by 3% to $536 million. However, Adjusted Cash Receipts increased by 10% to $524 million, driven by the cystic fibrosis franchise, Xtandi, and Tremfya. The company also announced transactions of up to $2.5 billion year-to-date and raised full-year 2022 guidance for Adjusted Cash Receipts to $2,275 to $2,350 million.
- Net cash provided by operating activities increased 8% to $575 million.
- Adjusted Cash Receipts increased 10% to $524 million, driven by a double-digit increase in royalties from the cystic fibrosis franchise, Xtandi and the addition of Tremfya.
- Adjusted EBITDA grew 10% to $480 million, driven by strong growth in Adjusted Cash Receipts.
- Adjusted Cash Flow increased 12% to $482 million.
Headline financials
Revenue & EPS history
Royalty Pharma · Revenue · Quarterly
$536M
Revenue by segment
Royalty Pharma · $542M total across 11 segments · Q2 2022
- Cystic Fibrosis Franchise$182M+16.7%33.6%
- Tysabri$93M+1.1%17.2%
- Imbruvica$80M-8.0%14.8%
- Xtandi$52M+44.4%9.6%
- Other Products$50M-2.0%9.2%
- Promacta$35M+9.4%6.5%
- Tremfya$18M—3.3%
- Cabometyx/Cometriq$13M+30.0%2.4%
- Evrysdi$8M+166.7%1.5%
- Trodelvy$6M+100.0%1.1%
- Erleada$5M+66.7%0.9%
Forward guidance
Royalty Pharma anticipates full-year 2022 Adjusted Cash Receipts to be between $2,275 million and $2,350 million (+7% to 10% year/year), excluding transactions announced subsequent to the date of this release.
Headwinds
- Guidance reflects an estimated foreign exchange impact of approximately -3% to -4% (-$65 million to -$85 million) for full-year 2022 year/year Adjusted Cash Receipts growth, assuming current exchange rates prevail for the balance of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
-0.6%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+0.9%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+6.8%
Q3 2025
Best reaction
-8.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -1.0% | +2.4% | +10.7% | |
| Q4 2025 | +0.1% | +2.2% | +3.3% | |
| Q3 2025 | +6.8% | +1.8% | +5.0% | |
| Q1 2025 | +0.9% | +0.2% | +3.1% | |
| Q4 2024 | +1.7% | +2.0% | +3.0% | |
| Q3 2024 | -3.7% | -4.3% | -5.9% | |
| Q2 2024 | -3.6% | -1.4% | +5.3% | |
| Q1 2024 | +0.4% | +0.3% | -1.9% | |
| Q4 2023 | +2.1% | +3.4% | +2.7% | |
| Q3 2023 | -0.5% | -1.6% | +3.7% | |
| Q2 2023 | -0.9% | -1.1% | -6.4% | |
| Q1 2023 | -4.7% | -2.7% | -2.8% | |
| Q4 2022 | -2.0% | -0.4% | -8.8% | |
| Q3 2022 | +1.6% | +3.7% | -0.1% | |
| Q2 2022 | -0.9% | +1.9% | -1.8% | |
| Q1 2022 | -8.1% | -12.8% | -6.2% | |
| Q4 2021 | +3.6% | +0.8% | +1.7% | |
| Q3 2021 | +1.5% | +5.3% | -4.6% | |
| Q2 2021 | +2.7% | +5.0% | +5.6% | |
| Q1 2021 | -2.2% | -1.8% | +12.4% | |
| Q4 2020 | -2.1% | +1.1% | -1.5% | |
| Q3 2020 | -1.6% | +2.8% | +10.3% | |
| Q2 2020 | -3.0% | -4.2% | -5.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro